Fate Therapeutics, Inc.
FATE
$2.44
-$0.06-2.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 11.48% | 17.03% | 37.92% | 32.36% | 11.34% |
| Total Depreciation and Amortization | -15.19% | -12.45% | -36.36% | -29.95% | -30.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.12% | -41.27% | -76.96% | -60.61% | 18.13% |
| Change in Net Operating Assets | 1,534.25% | -11.00% | 155.26% | -83.89% | 101.93% |
| Cash from Operations | 4.69% | 8.83% | 16.13% | 17.15% | 23.89% |
| Capital Expenditure | 94.13% | 80.02% | -1,116.33% | -345.05% | -2,570.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.73% | -45.69% | 24.75% | -9.57% | 139.07% |
| Cash from Investing | -25.70% | -44.73% | 21.10% | -16.45% | 136.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -0.08% | -- | -46.01% | -- | -31.70% |
| Cash from Financing | 31.02% | -- | -46.01% | -- | 4.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -94.52% | -181.62% | 424.12% | 84.16% | 95.65% |